Clinical trials: Prostate Cancer Intermediate Risk Treated by Radiosurgery
Prostate Cancer Early Risk Treated by Radiosurgery, Prostate Cancer Intermediate Risk Treated by Radiosurgery
Multi-Institutional Registry for Prostate Cancer Radiosurgery
To address pertinent questions regarding the utilization of stereotactic Body Radiotherapy (SBRT) to treat prostate cancer. The Florida Robotic Radiosurgery Association (FRRA) launched the first registry for prostate cancer…
- Trial name
- RPCR (NCT01226004)
- Where
- 44 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- RPCR, Inc.
Prostate Cancer
Stereotactic Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00619515
- Testing
- questionnaire administration, implanted fiducial-based imaging, stereotactic radiosurgery
- Where
- 4 sites in United States
- Volunteers
- 73 people
- Sponsor
- Case Comprehensive Cancer Center
Macroscopic Tumor Visualized at MRI, Tumor Size Allowing Partial Prostate Treatment Volume
Stereotactic Focal Radiotherapy as an Alternative Treatment to Active Surveillance for Low and Intermediate Risk Prostate Cancer
*Rationale : Active surveillance of prostate cancer helps to avoid the morbidity associated with curative radical prostatectomy /radiotherapy in patients with early stage disease.
- Conditions
- Macroscopic Tumor Visualized at MRI, Tumor Size Allowing Partial Prostate Treatment Volume, CAPRA SCORE ≤5
- Trial name
- TOPPGUN-RS (NCT07152067)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- 2 sites in Belgium
- Volunteers
- 146 people
- Sponsor
- Centre Hospitalier Universitaire de Liege